Molecular Partners Ag (MOLN) Common Equity (2020 - 2026)

Molecular Partners Ag (MOLN) has reported Common Equity for 7 consecutive years, with $74.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 42.51% year-over-year to $74.1 million in Q2 2026; TTM through Jun 2026 was $74.1 million, a 42.51% decrease from a year earlier, with the FY2025 full-year figure at $96.9 million, down 39.82% from the prior year.
• Common Equity was $74.1 million for Q2 2026 at Molecular Partners Ag, down from $87.4 million in the prior quarter.
• Over five years, Common Equity peaked at $286.4 million in Q1 2022 and troughed at $74.1 million in Q2 2026.
• A 5-year average of $177.7 million and a median of $172.0 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 109.8% in 2022 and tumbled 42.51% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $244.1 million in 2022, then declined by 18.52% to $198.9 million in 2023, then decreased by 18.71% to $161.7 million in 2024, then tumbled by 37.83% to $100.5 million in 2025, then retreated by 26.3% to $74.1 million in 2026.
• The last three Common Equity figures came in at $74.1 million (Q2 2026), $87.4 million (Q1 2026), and $100.5 million (Q4 2025), per Business Quant data.